DANTRIUM Side Effects

7020434-9 | Hyperhidrosis, Incorrect Dose Administered, Pneumonia Aspiration, Respiratory Rate Increased, Tachycardia
on Sep 20, 2010 Male patient from UNITED KINGDOM , 54 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?), musculoskeletal stiffness and was treated with Dantrium (View Usage). Patient experienced the following unwanted or unexpected effects: hyperhidrosis, incorrect dose administered, pneumonia aspiration, respiratory rate increased, tachycardia. Dantrium dosage: 100 Mg, Qid, Oral. During the same period patient was treated with BACLOFEN (View Baclofen Review and Baclofen Label ), TIZANIDINE HCL (View Tizanidine Hcl Review and Tizanidine Hcl Label ), ESCITALOPRAM (View Escitalopram Review and Escitalopram Label ), ATENOLOL (View Atenolol Review and Atenolol Label ), QUININE (QUININE HYDROCHLORIDE) (View Quinine (quinine Hydrochloride) Review and Quinine (quinine Hydrochloride) Label ), ANTIBIOTICS (View Antibiotics Review and Antibiotics Label ). Patient was hospitalized.

7015387-3 | Anaphylactic Shock, Dysphagia, Heart Rate Increased, Hypoxic-ischaemic Encephalopathy, Movement Disorder, Speech Disorder
Patient was taking Dantrium (View Usage). Patient had the following side effects: anaphylactic shock, dysphagia, heart rate increased, hypoxic-ischaemic encephalopathy, movement disorder (What is movement disorder?), speech disorder on Sep 09, 2010 from JAPAN Additional patient health information: Female patient , 14 years of age, weighting 105.8 lb, was diagnosed with neuroleptic malignant syndrome and. Dantrium dosage: 40 Mg In 50 Ml Saline Over 60 Minutes, Iv Drip. During the same period patient was treated with FAMOTIDINE (View Famotidine Review and Famotidine Label ), KAYTWO (MENATETRENONE) (View Kaytwo (menatetrenone) Review and Kaytwo (menatetrenone) Label ), SOLU CORTEF (View Solu-cortef Review and Solu-cortef Label ), CARBENIN (BETAMIPRON, PANIPENEM) (View Carbenin (betamipron, Panipenem) Review and Carbenin (betamipron, Panipenem) Label ), DORMICUM (NITRAZEPAM) (View Dormicum (nitrazepam) Review and Dormicum (nitrazepam) Label ), RECOMODULIN (View Recomodulin Review and Recomodulin Label ), DOPAMINE HCL (View Dopamine Hcl Review and Dopamine Hcl Label ), FERON (INTERFERON BETA) (View Feron (interferon Beta) Review and Feron (interferon Beta) Label ). Patient was hospitalized and became disabled.

6963817-5 | Bacterial Infection, Heart Rate Increased, Hypercreatinaemia, Hyperthermia, Hypotension, Liver Disorder, Lung Infiltration, Neuroleptic Malignant Syndrome, Pneumonia
Adverse event was reported on Aug 17, 2010 by a Male patient taking Dantrium (View Usage) (Dosage: 75 Mg, Daily, Oral) . Location: JAPAN , 57 years of age, After Dantrium was administered, patient had the following side effects: bacterial infection (What is bacterial infection?), heart rate increased, hypercreatinaemia, hyperthermia, hypotension, liver disorder, lung infiltration, neuroleptic malignant syndrome, pneumonia (What is pneumonia?). During the same period patient was treated with FLUID REPLACEMENT (View Fluid Replacement Review and Fluid Replacement Label ), MEROPENEM (MEROPENENM) (View Meropenem (meropenenm) Review and Meropenem (meropenenm) Label ), LEVOFLOXACIN (View Levofloxacin Review and Levofloxacin Label ), CEFOTIAM (CEFOTIAM) (View Cefotiam (cefotiam) Review and Cefotiam (cefotiam) Label ), MINOCYCLINE (MINOCYCLINE HYDROCHLORIDE) (View Minocycline (minocycline Hydrochloride) Review and Minocycline (minocycline Hydrochloride) Label ), LINEZOLID (View Linezolid Review and Linezolid Label ), DOPAMINE HCL (View Dopamine Hcl Review and Dopamine Hcl Label ), GABEXATE (GABEXATE) (View Gabexate (gabexate) Review and Gabexate (gabexate) Label ).

6939468-5 | Bacterial Infection, Cerebral Infarction, Depressed Level Of Consciousness, Hyponatraemia, Hypotension, Liver Disorder, Neuroleptic Malignant Syndrome, Platelet Count Decreased, Pneumonia
on Aug 04, 2010 Male patient from JAPAN , 57 years of age, was treated with Dantrium (View Usage). Patient experienced the following unwanted or unexpected effects: bacterial infection (What is bacterial infection?), cerebral infarction, depressed level of consciousness, hyponatraemia, hypotension, liver disorder, neuroleptic malignant syndrome, platelet count decreased, pneumonia (What is pneumonia?). Dantrium dosage: 75 Mg, Daily, Oral. During the same period patient was treated with FLUID REPLACEMENT (View Fluid Replacement Review and Fluid Replacement Label ), MEROPENEM (View Meropenem Review and Meropenem Label ), LEVOFLOXACIN (View Levofloxacin Review and Levofloxacin Label ), CEFOTIAM (CEFOTIAM) (View Cefotiam (cefotiam) Review and Cefotiam (cefotiam) Label ), MINOCYCLINE (MINOCYCLINE HYDROCHLORIDE) (View Minocycline (minocycline Hydrochloride) Review and Minocycline (minocycline Hydrochloride) Label ), LINEZOLID (View Linezolid Review and Linezolid Label ), DOPAMINE HCL (View Dopamine Hcl Review and Dopamine Hcl Label ), GABEXATE (GABEXATE) (View Gabexate (gabexate) Review and Gabexate (gabexate) Label ).


6931243-0 | Bladder Transitional Cell Carcinoma
on Jul 29, 2010 Male patient from JAPAN , 22 years of age, was treated with Dantrium (View Usage). Patient had the following side effects: bladder transitional cell carcinoma. Dantrium dosage: Oral. During the same period patient was treated with PHENOBARBITAL TAB (Oral) (View Phenobarbital Tab Review and Phenobarbital Tab Label ).

6931228-4 | Bladder Cancer, Post Procedural Complication, Respiratory Depression
Patient was taking Dantrium (View Usage). After Dantrium was administered, patient had the following side effects: bladder cancer (What is bladder cancer?), post procedural complication, respiratory depression on Jul 29, 2010 from JAPAN Additional patient health information: Male patient , 17 years of age, . Dantrium dosage: Oral. During the same period patient was treated with PHENOBARBITAL TAB (Oral) (View Phenobarbital Tab Review and Phenobarbital Tab Label ).

6931227-2 | Bladder Cancer
Adverse event was reported on Jul 29, 2010 by a Male patient taking Dantrium (View Usage) (Dosage: Oral) . Location: JAPAN , 26 years of age, Patient experienced the following unwanted or unexpected effects: bladder cancer (What is bladder cancer?). During the same period patient was treated with PHENOBARBITAL TAB (Oral) (View Phenobarbital Tab Review and Phenobarbital Tab Label ).

6914415-0 | Blood Creatine Phosphokinase Mb Increased, Blood Pressure Immeasurable, Dehydration, Dry Mouth, Infusion Related Reaction, Neuroleptic Malignant Syndrome, Peripheral Coldness, Po2 Decreased, Rhabdomyolysis
on Jul 22, 2010 Female patient from JAPAN , child 3 years of age, was diagnosed with cerebral palsy, infantile spasms and was treated with Dantrium (View Usage). Patient had the following side effects: blood creatine phosphokinase mb increased, blood pressure immeasurable, dehydration, dry mouth, infusion related reaction, neuroleptic malignant syndrome, peripheral coldness, po2 decreased, rhabdomyolysis. Dantrium dosage: 25 Mg, Daily, Via Gastrostomy Tube, Other. During the same period patient was treated with DEPAKENE (140 Mg, Bid, Via Gastrostomy Tube, Other) (View Depakene Review and Depakene Label ), WINTERMIN (CHLORPROMAZINE HYDROCHLORIDE) (5 Mg, Tid, Via Gastrostomy Tube, Other) (View Wintermin (chlorpromazine Hydrochloride) Review and Wintermin (chlorpromazine Hydrochloride) Label ).

6883029-3 | Condition Aggravated, Dysphagia, Sputum Retention
on Jul 12, 2010 Male patient from JAPAN , 29 years of age, was diagnosed with neuroleptic malignant syndrome and was treated with Dantrium (View Usage). After Dantrium was administered, patient had the following side effects: condition aggravated, dysphagia, sputum retention. Dantrium dosage: 40 Mg, Daily.

6869837-3 | Collapse Of Lung, Diaphragmatic Disorder, Dyspnoea, Fatigue, Respiratory Acidosis, Respiratory Failure, Somnolence
Patient was taking Dantrium (View Usage). Patient experienced the following unwanted or unexpected effects: collapse of lung, diaphragmatic disorder, dyspnoea, fatigue, respiratory acidosis, respiratory failure, somnolence on Jul 07, 2010 from UNITED KINGDOM Additional patient health information: Male patient , 60 years of age, was diagnosed with muscle spasticity and. Dantrium dosage: 50 Mg X3x/day + 75 Mg X 1/night, Oral. Patient was hospitalized.

6869782-3 | Neuroleptic Malignant Syndrome, Peripheral Coldness
Adverse event was reported on Jul 06, 2010 by a Female patient taking Dantrium (View Usage) (Dosage: 25 Mg, Daily, Via Gastrostomy Tube, Other) was diagnosed with cerebral palsy, infantile spasms and. Location: JAPAN , child 3 years of age, Patient had the following side effects: neuroleptic malignant syndrome, peripheral coldness. During the same period patient was treated with DEPAKENE (140 Mg, Bid, Via Gastrostomy Tube, Other) (View Depakene Review and Depakene Label ), WINTERMIN (CHLORPROMAZINE HYDROCHLORIDE) (5 Mg, Tid, Via Gastrostomy Tube, Other) (View Wintermin (chlorpromazine Hydrochloride) Review and Wintermin (chlorpromazine Hydrochloride) Label ).

6847316-7 | Dehydration, Neuroleptic Malignant Syndrome, Vomiting
on Jun 11, 2010 Female patient from JAPAN , child 3 years of age, was diagnosed with dystonia (What is dystonia?), epilepsy (What is epilepsy?) and was treated with Dantrium (View Usage). After Dantrium was administered, patient had the following side effects: dehydration, neuroleptic malignant syndrome, vomiting. Dantrium dosage: Oral. During the same period patient was treated with DEPAKENE (View Depakene Review and Depakene Label ), CHLORPROMAZINE HCL (View Chlorpromazine Hcl Review and Chlorpromazine Hcl Label ).

6811763-X | Delirium, Epilepsy, Moaning, Muscular Weakness, Respiration Abnormal, Respiratory Depression, Sleep Terror, Urinary Tract Infection
on Jun 14, 2010 Female patient from JAPAN , 68 years of age, weighting 77.16 lb, was diagnosed with neuroleptic malignant syndrome, depression (What is depression?), insomnia and was treated with Dantrium (View Usage). Patient experienced the following unwanted or unexpected effects: delirium, epilepsy (What is epilepsy?), moaning, muscular weakness, respiration abnormal, respiratory depression, sleep terror, urinary tract infection (What is urinary tract infection?). Dantrium dosage: 25 Mg, Tid, Oral; 25 Mg, Bid, Oral; 25 Mg, Qd. During the same period patient was treated with DEPAS (ETIZOLAM) (0.5 Mg, Qd, Oral) (View Depas (etizolam) Review and Depas (etizolam) Label ), ZANTAC (RANITIDINE HYDROCHLORIDE) TABLET (View Zantac (ranitidine Hydrochloride) Tablet Review and Zantac (ranitidine Hydrochloride) Tablet Label ), EBRANTIL (URAPIDIL) TABLET (View Ebrantil (urapidil) Tablet Review and Ebrantil (urapidil) Tablet Label ), MEDITRANS (GLYCERYL TRINITRATE) (GLYCERYL TRINITRATE) TAPE (INCLUDING (View Meditrans (glyceryl Trinitrate) (glyceryl Trinitrate) Tape (including Review and Meditrans (glyceryl Trinitrate) (glyceryl Trinitrate) Tape (including Label ), GASLON (IRSOGLADINE MALEATE) (View Gaslon (irsogladine Maleate) Review and Gaslon (irsogladine Maleate) Label ).

6809374-5 | Dehydration, Neuroleptic Malignant Syndrome, Vomiting
Patient was taking Dantrium (View Usage). Patient had the following side effects: dehydration, neuroleptic malignant syndrome, vomiting on Jun 11, 2010 from JAPAN Additional patient health information: Female patient , child 3 years of age, was diagnosed with dystonia (What is dystonia?), epilepsy (What is epilepsy?) and. Dantrium dosage: , Oral. During the same period patient was treated with DEPAKENE (View Depakene Review and Depakene Label ), CHLORPROMAZINE HCL (View Chlorpromazine Hcl Review and Chlorpromazine Hcl Label ).

6781527-4 | Delirium, Depression, Dyspnoea, Epilepsy, Insomnia, Muscular Weakness, Respiratory Depression, Sleep Terror
Adverse event was reported on Jun 02, 2010 by a Female patient taking Dantrium (View Usage) (Dosage: 25mg Tid Oral) was diagnosed with neuroleptic malignant syndrome, depression (What is depression?), insomnia and. Location: JAPAN , 68 years of age, After Dantrium was administered, patient had the following side effects: delirium, depression (What is depression?), dyspnoea, epilepsy (What is epilepsy?), insomnia, muscular weakness, respiratory depression, sleep terror. During the same period patient was treated with DEPAS (0.5 Mg, Qd, Oral) (View Depas Review and Depas Label ), ZANTAC (RANITIDINE HYDROCHLORIDE) TABLET (View Zantac (ranitidine Hydrochloride) Tablet Review and Zantac (ranitidine Hydrochloride) Tablet Label ).

6766670-8 | Abortion Induced
on May 31, 2010 Female patient from FRANCE , 21 years of age, was diagnosed with paraplegia and was treated with Dantrium (View Usage). Patient experienced the following unwanted or unexpected effects: abortion induced. Dantrium dosage: 5 Mg, Tid, Oral. During the same period patient was treated with PRAXINOR (CAFEDRINE HYDROCHLORIDE, THEODRENALINE HYDROCHLORIDE) TABLET (Started Before Pregnancy - 3 Tablets/day, Oral) (View Praxinor (cafedrine Hydrochloride, Theodrenaline Hydrochloride) Tablet Review and Praxinor (cafedrine Hydrochloride, Theodrenaline Hydrochloride) Tablet Label ), BACLOFEN (Started Before Pregnancy - 20 Mg/ Day, Oral) (View Baclofen Review and Baclofen Label ), PERISTALTINE (RHAMNUS PURSHIANA EXTRACT) (Started Beore Pregnancy - 1 Df, Daily, Oral; 1 Df Daily Every Two Days, Oral) (View Peristaltine (rhamnus Purshiana Extract) Review and Peristaltine (rhamnus Purshiana Extract) Label ), HEPTAMINOL (HEPTAMINOL) (187.8 Mg, Qid, Oral) (View Heptaminol (heptaminol) Review and Heptaminol (heptaminol) Label ), DITROPAN (15 Mg, Daily, Oral) (View Ditropan Review and Ditropan Label ), VACCINIUM MACROCARPON (VACCINIUM MACROCARPON) (1000 Mg, Daily, Oral) (View Vaccinium Macrocarpon (vaccinium Macrocarpon) Review and Vaccinium Macrocarpon (vaccinium Macrocarpon) Label ), LEXOMIL (BROMAZEPAM) (Started Efore Pregnancy - 0.25 Df Daily, Oral) (View Lexomil (bromazepam) Review and Lexomil (bromazepam) Label ), VENLAFAXINE HCL (View Venlafaxine Hcl Review and Venlafaxine Hcl Label ). Patient was hospitalized.

6677099-5 | Infusion Site Thrombosis
on Feb 05, 2009 Male patient from UNITED STATES , 20 years of age, was diagnosed with hyperthermia malignant and was treated with Dantrium (View Usage). Patient had the following side effects: infusion site thrombosis. Dantrium dosage: Intravenous. Patient was hospitalized.

6642631-4 | Acute Respiratory Failure, Pulmonary Oedema
Patient was taking Dantrium (View Usage). After Dantrium was administered, patient had the following side effects: acute respiratory failure, pulmonary oedema on Mar 02, 2010 from JAPAN Additional patient health information: Female patient , 78 years of age, weighting 88.18 lb, was diagnosed with neuroleptic malignant syndrome and. Dantrium dosage: 40 Mg, Daily, Iv Drip. During the same period patient was treated with MENESIT (CARBIDOPA, LEVODOPA) (View Menesit (carbidopa, Levodopa) Review and Menesit (carbidopa, Levodopa) Label ), ROCEPHIN (View Rocephin Review and Rocephin Label ).

6477003-9 | Cerebrovascular Accident
Adverse event was reported on Nov 19, 2009 by a Male patient taking Dantrium (View Usage) (Dosage: 50 Mg, Bid - Long Term, Oral) was diagnosed with muscle spasticity and. Location: UNITED KINGDOM , 74 years of age, Patient experienced the following unwanted or unexpected effects: cerebrovascular accident. Patient was hospitalized.

6414542-0 | Cytolytic Hepatitis, Hepatomegaly, Hypotension, International Normalised Ratio Increased, Overdose
on Oct 08, 2009 Male patient from FRANCE , 78 years of age, was diagnosed with muscle spasticity and was treated with Dantrium (View Usage). Patient had the following side effects: cytolytic hepatitis, hepatomegaly, hypotension, international normalised ratio increased, overdose. Dantrium dosage: 125 Mg Daily For At Least 2 Years, Oral. During the same period patient was treated with TRAMADOL HCL (2 Dosage Forms Daily (long Term Treatment), Oral) (View Tramadol Hcl Review and Tramadol Hcl Label ), ACETAMINOPHEN (1 To 4 G/ Day (long Term Treatment), Oral) (View Acetaminophen Review and Acetaminophen Label ), BISOPROLOL FUMARATE (View Bisoprolol Fumarate Review and Bisoprolol Fumarate Label ), PERINDOPRIL ERBUMINE (View Perindopril Erbumine Review and Perindopril Erbumine Label ), AMIODARONE HCL (View Amiodarone Hcl Review and Amiodarone Hcl Label ), PREVISCAN (FLUINDIONE) (View Previscan (fluindione) Review and Previscan (fluindione) Label ), ZOLPIDEM TARTRATE (View Zolpidem Tartrate Review and Zolpidem Tartrate Label ), LASIX (View Lasix Review and Lasix Label ). Patient was hospitalized.

6355159-6 | Pulmonary Embolism
on Aug 26, 2009 Male patient from FRANCE , 63 years of age, weighting 187.4 lb, was diagnosed with cerebrovascular accident and was treated with Dantrium (View Usage). After Dantrium was administered, patient had the following side effects: pulmonary embolism (What is pulmonary embolism?). Dantrium dosage: 50 Mg, Bid (2 Dose Forms In Morning And 2 In The Evening), Oral. During the same period patient was treated with VERAPAMIL (View Verapamil Review and Verapamil Label ). Patient was hospitalized.

6348177-5 | Blood Potassium Increased, Cardiac Arrest, Dialysis, Respiratory Arrest
Patient was taking Dantrium (View Usage). Patient experienced the following unwanted or unexpected effects: blood potassium increased, cardiac arrest (What is cardiac arrest?), dialysis (What is dialysis?), respiratory arrest on Aug 25, 2009 from JAPAN Additional patient health information: Female patient , 74 years of age, was diagnosed with muscle spasms and. Dantrium dosage: 25 Mg, Daily, Oral. During the same period patient was treated with VERAPAMIL HYDROCHLORIDE (View Verapamil Hydrochloride Review and Verapamil Hydrochloride Label ), OLMESARTAN MEDOXOMIL (View Olmesartan Medoxomil Review and Olmesartan Medoxomil Label ), FENOFIBRATE (View Fenofibrate Review and Fenofibrate Label ), INDERAL (View Inderal Review and Inderal Label ), NOVOLOG (View Novolog Review and Novolog Label ), LANTUS (View Lantus Review and Lantus Label ).

6305575-3 | Nervousness, Pneumonia, Purpura, Toxic Skin Eruption
Adverse event was reported on Jul 24, 2009 by a Female patient taking Dantrium (View Usage) (Dosage: 25 Mg, Daily, Oral) was diagnosed with muscle spasms, osteoarthritis (What is osteoarthritis?) and. Location: JAPAN , 68 years of age, weighting 110.2 lb, Patient had the following side effects: nervousness, pneumonia (What is pneumonia?), purpura, toxic skin eruption. During the same period patient was treated with CELECOXIB (100 Mg, Bid, Oral) (View Celecoxib Review and Celecoxib Label ), LIMARMONE (LIMAPROST) (15 Ug, Daily, Oral) (View Limarmone (limaprost) Review and Limarmone (limaprost) Label ), ASPARA CA (ASPARTATE CALCIUM) (View Aspara-ca (aspartate Calcium) Review and Aspara-ca (aspartate Calcium) Label ), ARTZ (HYALURONATE SODIUM) (View Artz (hyaluronate Sodium) Review and Artz (hyaluronate Sodium) Label ), ALDACTONE (View Aldactone Review and Aldactone Label ), LASIX (View Lasix Review and Lasix Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ). Patient was hospitalized.

6289170-0 | Nervousness, Oropharyngeal Pain, Platelet Count Decreased, Pneumonia, Purpura, Toxic Skin Eruption
on Jul 15, 2009 Female patient from JAPAN , 68 years of age, weighting 110.2 lb, was diagnosed with muscle spasms, osteoarthritis (What is osteoarthritis?) and was treated with Dantrium (View Usage). After Dantrium was administered, patient had the following side effects: nervousness, oropharyngeal pain, platelet count decreased, pneumonia (What is pneumonia?), purpura, toxic skin eruption. Dantrium dosage: 25 Mg, Daily, Oral. During the same period patient was treated with CELECOXIB (100 Mg, Bid, Oral) (View Celecoxib Review and Celecoxib Label ), LIMARMONE (LIMAPROST) (15 Ug, Daily, Oral) (View Limarmone (limaprost) Review and Limarmone (limaprost) Label ), ASPARA CA (ASPARTATE CALCIUM) (View Aspara-ca (aspartate Calcium) Review and Aspara-ca (aspartate Calcium) Label ), ARTZ (HYALURONATE SODIUM) (View Artz (hyaluronate Sodium) Review and Artz (hyaluronate Sodium) Label ), ALDACTONE (View Aldactone Review and Aldactone Label ), LASIX (View Lasix Review and Lasix Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ). Patient was hospitalized.

6269261-0 | Chills, Oropharyngeal Pain, Pneumonia, Toxic Skin Eruption
on Jun 30, 2009 Female patient from JAPAN , 68 years of age, was diagnosed with osteoarthritis (What is osteoarthritis?) and was treated with Dantrium (View Usage). Patient experienced the following unwanted or unexpected effects: chills, oropharyngeal pain, pneumonia (What is pneumonia?), toxic skin eruption. Dantrium dosage: 25 Mg, Daily, Oral. During the same period patient was treated with CELECOXIB (200 Mg, Daily, Oral) (View Celecoxib Review and Celecoxib Label ), ASPARA CA (ASPARTATE CALCIUM) (View Aspara-ca (aspartate Calcium) Review and Aspara-ca (aspartate Calcium) Label ), ARTZ (HYALURONATE SODIUM) (View Artz-(hyaluronate Sodium) Review and Artz-(hyaluronate Sodium) Label ). Patient was hospitalized.

6178592-4 | Hyponatraemia, Inappropriate Antidiuretic Hormone Secretion
Patient was taking Dantrium (View Usage). Patient had the following side effects: hyponatraemia, inappropriate antidiuretic hormone secretion on Apr 16, 2009 from JAPAN Additional patient health information: Female patient , 68 years of age, was diagnosed with neuroleptic malignant syndrome and. Dantrium dosage: 25 Mg, Tid, Oral. During the same period patient was treated with NEODOPASOL (BENSERAZIDE HYDROCHLORIDE, LEVODOPA) (View Neodopasol (benserazide Hydrochloride, Levodopa) Review and Neodopasol (benserazide Hydrochloride, Levodopa) Label ), PERMAX /00613002/ (PERGOLIDE MESILATE) (View Permax /00613002/ (pergolide Mesilate) Review and Permax /00613002/ (pergolide Mesilate) Label ), ARTANE (View Artane Review and Artane Label ), FP (SELEGILINE HYDROCHLORIDE) (View Fp (selegiline Hydrochloride) Review and Fp (selegiline Hydrochloride) Label ), BI SIFROL (PRAMIPEXOLE DIHYDROCHLORIDE) (View Bi Sifrol (pramipexole Dihydrochloride) Review and Bi Sifrol (pramipexole Dihydrochloride) Label ).

6147104-3 | Asthenia, Muscular Weakness, Respiratory Arrest
Adverse event was reported on Mar 19, 2009 by a Female patient taking Dantrium (View Usage) (Dosage: 150 Mg Daily, As Opened Capsules Through A Tube, Other) was diagnosed with muscle rigidity and. Location: JAPAN , 37 years of age, After Dantrium was administered, patient had the following side effects: asthenia, muscular weakness, respiratory arrest.

6125350-2 | Hyponatraemia, Inappropriate Antidiuretic Hormone Secretion
on Mar 05, 2009 Female patient from JAPAN , 68 years of age, was diagnosed with neuroleptic malignant syndrome and was treated with Dantrium (View Usage). Patient experienced the following unwanted or unexpected effects: hyponatraemia, inappropriate antidiuretic hormone secretion. Dantrium dosage: 25 Mg, Tid, Oral. During the same period patient was treated with NEODOPASOL (BENSERAZIDE HYDROCHLORIDE, LEVODOPA) (View Neodopasol (benserazide Hydrochloride, Levodopa) Review and Neodopasol (benserazide Hydrochloride, Levodopa) Label ), PERMAX /00613002/ (PERGOLIDE MESILATE) TABLET (View Permax /00613002/ (pergolide Mesilate) Tablet Review and Permax /00613002/ (pergolide Mesilate) Tablet Label ), ARTANE (View Artane Review and Artane Label ), FP (SELEGILINE HYDROCHLORIDE) (View Fp (selegiline Hydrochloride) Review and Fp (selegiline Hydrochloride) Label ), BI SIFROL (PRAMIPEXOLE DIHYDROCHLORIDE) TABLET (View Bi Sifrol (pramipexole Dihydrochloride) Tablet Review and Bi Sifrol (pramipexole Dihydrochloride) Tablet Label ).

6119679-1 | Hyponatraemia
on Feb 26, 2009 Female patient from JAPAN , 68 years of age, was treated with Dantrium (View Usage). Patient had the following side effects: hyponatraemia. Dantrium dosage: 75 Mg Daily, Oral.

6109228-6 | Blood Pressure Decreased, Dehydration
Patient was taking Dantrium (View Usage). After Dantrium was administered, patient had the following side effects: blood pressure decreased, dehydration on Feb 19, 2009 from JAPAN Additional patient health information: Male patient , 27 years of age, weighting 48.50 lb, was diagnosed with neuroleptic malignant syndrome and. Dantrium dosage: 20 Mg, Tid, Iv Drip. During the same period patient was treated with PARLODEL (2.5 Mg, Tid, Oral) (View Parlodel Review and Parlodel Label ), PRIMPERAN ELIXIR (View Primperan Elixir Review and Primperan Elixir Label ), GLUCOSE INJECTION (GLUCOSE INJECTION) (View Glucose Injection (glucose Injection) Review and Glucose Injection (glucose Injection) Label ), POTACOL R (CALCIUM CHLORIDE ANHYDROUS, MALTOSE, POTASSIUM CHLORIDE, SO (View Potacol-r (calcium Chloride Anhydrous, Maltose, Potassium Chloride, So Review and Potacol-r (calcium Chloride Anhydrous, Maltose, Potassium Chloride, So Label ), MEROPENEM (MEROPENEM) (View Meropenem (meropenem) Review and Meropenem (meropenem) Label ), LAXATIVES (View Laxatives Review and Laxatives Label ).

6109162-1 | Hyponatraemia
Adverse event was reported on Feb 19, 2009 by a Female patient taking Dantrium (View Usage) (Dosage: 75 Mg Daily, Oral) . Location: JAPAN , 68 years of age, Patient experienced the following unwanted or unexpected effects: hyponatraemia. Patient was hospitalized.

6077624-1 | Anxiety, Disorientation, Hypotonia, Loss Of Consciousness, Mydriasis, Suicide Attempt, Vomiting
on Jan 30, 2009 Male patient from GERMANY , 39 years of age, was diagnosed with intentional self-injury and was treated with Dantrium (View Usage). Patient had the following side effects: anxiety (What is anxiety?), disorientation, hypotonia, loss of consciousness, mydriasis, suicide attempt, vomiting. Dantrium dosage: Oral. During the same period patient was treated with AMITRIPTYLINE HYDROCHLORIDE (View Amitriptyline Hydrochloride Review and Amitriptyline Hydrochloride Label ), BROMAZINIL (BROMAZEPAM) (View Bromazinil (bromazepam) Review and Bromazinil (bromazepam) Label ), DRIDASE (OXYBUTYNIN HYDROCHLORIDE) (View Dridase (oxybutynin Hydrochloride) Review and Dridase (oxybutynin Hydrochloride) Label ), LIORESAL (View Lioresal Review and Lioresal Label ), MICTONORM (PROPIVERINE HYDROCHLORIDE) (View Mictonorm (propiverine Hydrochloride) Review and Mictonorm (propiverine Hydrochloride) Label ), TRANSDERM PATCH TRANSTEC (GLYCERYL TRINITRATE) (View Transderm Patch - Transtec (glyceryl Trinitrate) Review and Transderm Patch - Transtec (glyceryl Trinitrate) Label ). Patient was hospitalized.

6029400-3 | Inappropriate Antidiuretic Hormone Secretion
on Dec 19, 2008 Male patient from JAPAN , 65 years of age, was treated with Dantrium (View Usage). After Dantrium was administered, patient had the following side effects: inappropriate antidiuretic hormone secretion. Dantrium dosage: 50 Mg, Qd, Oral. During the same period patient was treated with PROTAGEN S (CHLORMADINONE ACETATE) (View Protagen S (chlormadinone Acetate) Review and Protagen S (chlormadinone Acetate) Label ), COLICOOL (CHLORPHENESIN CARBAMATE) (View Colicool (chlorphenesin Carbamate) Review and Colicool (chlorphenesin Carbamate) Label ), UBRETID (DISTIGMINE BROMIDE) (View Ubretid (distigmine Bromide) Review and Ubretid (distigmine Bromide) Label ), GLYCLAMIN (SODIUM GUALENATE) (View Glyclamin (sodium Gualenate) Review and Glyclamin (sodium Gualenate) Label ), EVIPROSTAT (CHIMAPHILA UMBRELLATA, EQISITUM ARVENSE. MG CHLORODE, POPU (View Eviprostat (chimaphila Umbrellata, Eqisitum Arvense. Mg Chlorode, Popu Review and Eviprostat (chimaphila Umbrellata, Eqisitum Arvense. Mg Chlorode, Popu Label ), MUCOSOLATE (AMROXOL HYDROCHLORIDE) (View Mucosolate (amroxol Hydrochloride) Review and Mucosolate (amroxol Hydrochloride) Label ).

6028834-0 | Dysuria, Urinary Retention
Patient was taking Dantrium (View Usage). Patient experienced the following unwanted or unexpected effects: dysuria, urinary retention on Dec 15, 2008 from JAPAN Additional patient health information: Male patient , 49 years of age, was diagnosed with muscle spasticity and. Dantrium dosage: 1 Df, Qd, Oral. During the same period patient was treated with LIORESAL (View Lioresal Review and Lioresal Label ).

6027986-6 | No Adverse Event
Adverse event was reported on Dec 10, 2008 by a Female patient taking Dantrium (View Usage) (Dosage: ) was diagnosed with neuroleptic malignant syndrome and. Location: JAPAN , 30 years of age, Patient had the following side effects: no adverse event.

6023019-6 | Urinary Retention
on Dec 08, 2008 Male patient from JAPAN , 49 years of age, was diagnosed with pain in extremity and was treated with Dantrium (View Usage). After Dantrium was administered, patient had the following side effects: urinary retention. Dantrium dosage: 1 Df, Qd, Oral. During the same period patient was treated with LIORESAL (View Lioresal Review and Lioresal Label ).

6003792-3 | Inappropriate Antidiuretic Hormone Secretion
on Nov 28, 2008 Male patient from JAPAN , 65 years of age, was treated with Dantrium (View Usage). Patient experienced the following unwanted or unexpected effects: inappropriate antidiuretic hormone secretion. Dantrium dosage: 50 Mg, Qd, Oral. During the same period patient was treated with PROTAGEN S (CHLORMADINONE ACETATE) (View Protagen S (chlormadinone Acetate) Review and Protagen S (chlormadinone Acetate) Label ), COLICOOL (CHLORPHENESIN CARBAMATE) (View Colicool (chlorphenesin Carbamate) Review and Colicool (chlorphenesin Carbamate) Label ), UBRETID (DISTIGMINE BROMIDE) (View Ubretid (distigmine Bromide) Review and Ubretid (distigmine Bromide) Label ), EVIPROSTAT /01150001/ (CHIMAPHILA UMBELLATA, EQUISETUM ARVENSE, MANGAN (View Eviprostat /01150001/ (chimaphila Umbellata, Equisetum Arvense, Mangan Review and Eviprostat /01150001/ (chimaphila Umbellata, Equisetum Arvense, Mangan Label ), MUCOSOLATE (AMBROXOL HYDROCHLORIDE) (View Mucosolate (ambroxol Hydrochloride) Review and Mucosolate (ambroxol Hydrochloride) Label ), GLYCLAMIN /00317302/ (SODIUM GUALENATE) (View Glyclamin /00317302/ (sodium Gualenate) Review and Glyclamin /00317302/ (sodium Gualenate) Label ).

5989583-8 | Cardiac Failure
Patient was taking Dantrium (View Usage). Patient had the following side effects: cardiac failure on Oct 27, 2008 from JAPAN Additional patient health information: Female patient , 30 years of age, was diagnosed with neuroleptic malignant syndrome and. Dantrium dosage: .

5934365-6 | Blood Alkaline Phosphatase Decreased, Eosinophil Count Increased, Gastrointestinal Motility Disorder, Haemoglobin Decreased, Hypercholesterolaemia, Hypertension, Lymphocyte Count Decreased, Pancreatic Pseudocyst, Pancreatitis Acute
Adverse event was reported on Oct 13, 2008 by a Male patient taking Dantrium (View Usage) (Dosage: 100mg Am 25mg Noon 50mg Pm, Oral; 175 Mg, Daily, Oral) was diagnosed with muscle spasticity, hypercholesterolaemia, hypertension and. Location: FRANCE , 55 years of age, After Dantrium was administered, patient had the following side effects: blood alkaline phosphatase decreased, eosinophil count increased, gastrointestinal motility disorder, haemoglobin decreased, hypercholesterolaemia, hypertension, lymphocyte count decreased, pancreatic pseudocyst, pancreatitis acute. During the same period patient was treated with FENOFIBRATE (1 Df, Evening,) (View Fenofibrate Review and Fenofibrate Label ), PRAVASTATIN (20 Mg, Daily, Oral) (View Pravastatin Review and Pravastatin Label ), CELECTOL (1 Df, Evening, Oral) (View Celectol Review and Celectol Label ), VISKEN (View Visken Review and Visken Label ), CREON /00014701/ (PANCREATIN) (View Creon /00014701/ (pancreatin) Review and Creon /00014701/ (pancreatin) Label ). Patient was hospitalized.

5912474-5 | Constipation, Diarrhoea, Gastrointestinal Motility Disorder, Pancreatic Duct Dilatation, Pancreatitis Acute, Scan Abdomen Abnormal
on Sep 19, 2008 Male patient from FRANCE , 55 years of age, was diagnosed with muscle spasticity, hypercholesterolaemia, hypertension and was treated with Dantrium (View Usage). Patient experienced the following unwanted or unexpected effects: constipation (What is constipation?), diarrhoea, gastrointestinal motility disorder, pancreatic duct dilatation, pancreatitis acute, scan abdomen abnormal. Dantrium dosage: 175 Mg, Daily, Oral; 175 Mg, Daily. During the same period patient was treated with FENOFIBRATE (View Fenofibrate Review and Fenofibrate Label ), PRAVASTATIN (20 Mg, Daily, Oral; 20 Mg, Daily, Oral) (View Pravastatin Review and Pravastatin Label ), CELECTOL (1 Df, Oral) (View Celectol Review and Celectol Label ), VISKEN (View Visken Review and Visken Label ), CREON (View Creon Review and Creon Label ), PANCREATIN TRIPLE STRENGTH CAP (View Pancreatin Triple Strength Cap Review and Pancreatin Triple Strength Cap Label ). Patient was hospitalized.

5911773-0 | Cerebrovascular Disorder, Grand Mal Convulsion, Insomnia, Meningitis, Neoplasm, Pneumatosis Intestinalis, Refusal Of Treatment By Patient, Status Epilepticus, Vomiting
on Sep 11, 2008 Male patient from JAPAN , 50 years of age, was diagnosed with neuroleptic malignant syndrome and was treated with Dantrium (View Usage). Patient had the following side effects: cerebrovascular disorder, grand mal convulsion, insomnia, meningitis (What is meningitis?), neoplasm, pneumatosis intestinalis, refusal of treatment by patient, status epilepticus, vomiting. Dantrium dosage: 75 Mg/day/50 Mg/day. During the same period patient was treated with PHENYTOIN 250 MG/DAY DR NI TO NI (View Phenytoin 250 Mg/day Dr Ni To Ni Review and Phenytoin 250 Mg/day Dr Ni To Ni Label ).

5911703-1 | Facial Spasm, Grand Mal Convulsion, Hyperthermia, Inflammation, Insomnia, Oxygen Saturation Decreased, Respiratory Disorder, Status Epilepticus
Patient was taking Dantrium (View Usage). After Dantrium was administered, patient had the following side effects: facial spasm, grand mal convulsion, hyperthermia, inflammation, insomnia, oxygen saturation decreased, respiratory disorder, status epilepticus on Sep 11, 2008 from JAPAN Additional patient health information: Male patient , 55 years of age, was diagnosed with neuroleptic malignant syndrome and. Dantrium dosage: 75 Mg, Daily, Iv Drip.

5809602-9 | Hypokalaemia
Adverse event was reported on Jun 25, 2008 by a Female patient taking Dantrium (View Usage) (Dosage: 40 Mg Daily, Iv Nos) was diagnosed with neuroleptic malignant syndrome and. Location: JAPAN , 69 years of age, Patient experienced the following unwanted or unexpected effects: hypokalaemia. During the same period patient was treated with CAPTOPRIL (View Captopril Review and Captopril Label ), NELBON (NITRAZEPAM) (View Nelbon (nitrazepam) Review and Nelbon (nitrazepam) Label ), PAXIL (View Paxil Review and Paxil Label ), DANTRIUM (DANTROLENE SODIUM) CAPSULES (25 Mg Three Times Daily , Oral) (View Dantrium (dantrolene Sodium) Capsules Review and Dantrium (dantrolene Sodium) Capsules Label ). Patient was hospitalized.

5656188-8 | Aplastic Anaemia, Vaginal Haemorrhage
on Feb 26, 2008 Female patient from UNITED KINGDOM , 32 years of age, was diagnosed with musculoskeletal stiffness, depression (What is depression?), multiple sclerosis (What is multiple sclerosis?), epilepsy (What is epilepsy?) and was treated with Dantrium (View Usage). Patient had the following side effects: aplastic anaemia, vaginal haemorrhage. Dantrium dosage: 50 Mg, 3 /day. During the same period patient was treated with CITALOPRAM HYDROBROMIDE (20 Mg, 1/day) (View Citalopram Hydrobromide Review and Citalopram Hydrobromide Label ), INTERFERON BETA(INTERFERON BETA) (250 Ug, Every 2 Day) (View Interferon Beta(interferon Beta) Review and Interferon Beta(interferon Beta) Label ), TEGRETOL (2.5 Mg, 2 /day) (View Tegretol Review and Tegretol Label ).

5580764-4 | Depressed Level Of Consciousness, Epilepsy, Hypothermia, Nervous System Disorder, Salivary Hypersecretion
on Dec 13, 2007 Male patient from FRANCE , 35 years of age, was diagnosed with muscle spasticity and was treated with Dantrium (View Usage). After Dantrium was administered, patient had the following side effects: depressed level of consciousness, epilepsy (What is epilepsy?), hypothermia (What is hypothermia?), nervous system disorder, salivary hypersecretion. Dantrium dosage: 100 Mg, 3/day, Oral.

5470661-7 | Acute Respiratory Distress Syndrome, Atrial Fibrillation, Cardiac Failure Congestive, Cardiomegaly, Haemodialysis, Hyperventilation, Hypoxia, Oxygen Saturation Decreased, Rales
Patient was taking Dantrium (View Usage). Patient experienced the following unwanted or unexpected effects: acute respiratory distress syndrome, atrial fibrillation (What is atrial fibrillation?), cardiac failure congestive, cardiomegaly, haemodialysis, hyperventilation, hypoxia, oxygen saturation decreased, rales on Sep 07, 2007 from JAPAN Additional patient health information: Male patient , 60 years of age, was diagnosed with neuroleptic malignant syndrome, cardiac failure and. Dantrium dosage: 25 Mg Three Times Daily, Oral 50 Mg Three Times Daily, Oral. During the same period patient was treated with LASIX (20 Mg Daily, Oral 40 Mg, Daily, Iv Bolus) (View Lasix Review and Lasix Label ), LEVOTHYROXINE SODIUM (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), GRAMALIL (TIAPRIDE HYDROCHLORIDE) (View Gramalil (tiapride Hydrochloride) Review and Gramalil (tiapride Hydrochloride) Label ), DEPAS (ETIZOLAM) (View Depas (etizolam) Review and Depas (etizolam) Label ), RISPERDAL (View Risperdal Review and Risperdal Label ). Patient was hospitalized.

5455011-4 | Cardio-respiratory Arrest
Adverse event was reported on Aug 30, 2007 by a Male patient taking Dantrium (View Usage) (Dosage: 40 Mg, 1 Only, Iv Drip; 60 Mg, 1 Only, Iv Drip) was diagnosed with neuroleptic malignant syndrome and. Location: JAPAN , 72 years of age, Patient had the following side effects: cardio-respiratory arrest. During the same period patient was treated with DORAL (View Doral Review and Doral Label ), GASMOTIN (MOSAPRIDE CITRATE) (View Gasmotin (mosapride Citrate) Review and Gasmotin (mosapride Citrate) Label ), RIZE (CLOTIAZEPAM) (View Rize (clotiazepam) Review and Rize (clotiazepam) Label ), DOXAZOSIN MESYLATE (View Doxazosin Mesylate Review and Doxazosin Mesylate Label ), JUVELA N (TOCOPHERYL NICOTINATE) (View Juvela N (tocopheryl Nicotinate) Review and Juvela N (tocopheryl Nicotinate) Label ), METHYCOBAL (CYANOCOBALAMIN) (View Methycobal (cyanocobalamin) Review and Methycobal (cyanocobalamin) Label ).

5446083-1 | Cardio-respiratory Arrest
on Aug 23, 2007 Male patient from JAPAN , 72 years of age, was diagnosed with neuroleptic malignant syndrome and was treated with Dantrium (View Usage). After Dantrium was administered, patient had the following side effects: cardio-respiratory arrest. Dantrium dosage: 40 Mg, 1 Only, Iv Drip; 60 Mg, 1 Only, Iv Drip; 60 Mg, 1 Only , Iv Drip.

5360783-3 | Blood Creatine Phosphokinase Increased, Body Temperature Increased, Hyperhidrosis, Muscle Tightness, Neuroleptic Malignant Syndrome, Tonic Convulsion, Tremor
on Jun 06, 2007 Male patient from JAPAN , 28 years of age, was diagnosed with analgesic effect and was treated with Dantrium (View Usage). Patient experienced the following unwanted or unexpected effects: blood creatine phosphokinase increased, body temperature increased, hyperhidrosis, muscle tightness, neuroleptic malignant syndrome, tonic convulsion, tremor. Dantrium dosage: 40 Mg. During the same period patient was treated with VEGETAMIN A (1 Unit) (View Vegetamin A Review and Vegetamin A Label ), GOODMIN (0.25 Mg) (View Goodmin Review and Goodmin Label ), ROHYPNOL (4 Mg) (View Rohypnol Review and Rohypnol Label ), TOLEDOMIN (100 Mg) (View Toledomin Review and Toledomin Label ), LEXOTAN (10 Mg) (View Lexotan Review and Lexotan Label ), PENTAZOCINE LACTATE (Unk) (View Pentazocine Lactate Review and Pentazocine Lactate Label ).

5301940-1 | Cardiac Failure Congestive, Pleural Effusion
Patient was taking Dantrium (View Usage). Patient had the following side effects: cardiac failure congestive, pleural effusion on Apr 16, 2007 from UNITED STATES Additional patient health information: Male patient , 80 years of age, weighting 150.0 lb, . Dantrium dosage: 25 Mg Twice Daily Po. Patient was hospitalized.